학술논문

FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer

Document Type

Article

Author

Casak, S.J.; Horiba, M.N.; Yuan, M.; Cheng, J.; Lemery, S.J.; Li Shen, Y.; Fu, W.; Moore, J.N.; Li, Y.; Bi, Y.; Auth, D.; Fesenko, N.; Kluetz, P.G.; Pazdur, R.; Fashoyin-Aje, L.A.

Source

In: Clinical Cancer Research. (Clinical Cancer Research, 1 November 2023, 29(21):4326-4330)

Subject

Language

English

ISSN

15573265
10780432

Online Access

Full Text (ECC - 개별구독 전자저널) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송